Clinical trial for Multiple Myeloma Refractory
Official title Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov ID: NCT07096778
What this study is testing
What is Inobrodib?
This is an investigational oral medicine being studied as a potential treatment for multiple myeloma that has come back or stopped responding to other therapies.
Also referred to as CCS1477.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether a new drug mix works against cancer. It is also looking at how safe the mix is and what side effects it causes.
- Who it's for
- You may be able to join if you have multiple myeloma that has come back.
- What's involved
- You would take inobrodib, pomalidomide, and dexamethasone. You would know which treatment you are getting.
- Time commitment
- The source text does not say how long the study lasts or how many visits are needed.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Male or female ≥18 years of age
- Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy
- Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2
- Adequate hematological, renal and hepatic function
- Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners
You likely can't join if
- Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of...
- Prior treatment with p300/CBP bromodomain inhibitors
- Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any...
- Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment
- Major surgery within 4 weeks of the first dose of study treatment
- Live vaccine within 4 weeks of study treatment
See the full eligibility criteria
- Male or female ≥18 years of age
- Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy
- Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2
- Adequate hematological, renal and hepatic function
- Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners
- Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest
- Prior treatment with p300/CBP bromodomain inhibitors
- Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide)
- Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment
- Major surgery within 4 weeks of the first dose of study treatment
- Live vaccine within 4 weeks of study treatment
- Active or unresolved adverse events
- Active malignancies (progressing or requiring change in treatment) in the last 24 months other than multiple myeloma
- Female patients who are pregnant or breast-feeding at any time during the study
- Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data
The study team makes the final eligibility decision.
Where it is enrolling
- Phoenix, Arizona, United States
- San Francisco, California, United States
- Jacksonville, Florida, United States
- Tampa, Florida, United States
- Atlanta, Georgia, United States
- Chicago, Illinois, United States
- Iowa City, Iowa, United States
- Bethesda, Maryland, United States
- Boston, Massachusetts, United States
- Ann Arbor, Michigan, United States
- Rochester, Minnesota, United States
- St Louis, Missouri, United States
- Omaha, Nebraska, United States
- Hackensack, New Jersey, United States
- New Brunswick, New Jersey, United States
- Charlotte, North Carolina, United States
- Winston-Salem, North Carolina, United States
- Cleveland, Ohio, United States
- Philadelphia, Pennsylvania, United States
- Seattle, Washington, United States
+ 9 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Phoenix, Arizona, United States; San Francisco, California, United States; Jacksonville, Florida, United States; Tampa, Florida, United States; Atlanta, Georgia, United States; Chicago, Illinois, United States and 23 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.